The stock of Metagenomi Inc (MGX) has gone up by 11.21% for the week, with a 99.47% rise in the past month and a 80.38% rise in the past quarter. The volatility ratio for the week is 15.29%, and the volatility levels for the past 30 days are 16.98% for MGX. The simple moving average for the past 20 days is 24.68% for MGX’s stock, with a -19.61% simple moving average for the past 200 days.
Is It Worth Investing in Metagenomi Inc (NASDAQ: MGX) Right Now?
Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MGX is 18.78M, and currently, shorts hold a 7.89% of that float. The average trading volume for MGX on December 26, 2024 was 1.78M shares.
MGX) stock’s latest price update
Metagenomi Inc (NASDAQ: MGX)’s stock price has plunge by -5.99relation to previous closing price of 4.01. Nevertheless, the company has seen a 11.21% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-11 that MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells EMERYVILLE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a talk titled “Specific and efficient genome editing with metagenomics-derived tools for in vivo and ex vivo therapeutic applications” at the Nature Conference: RNA at the Bench and Bedside IV.
Analysts’ Opinion of MGX
Many brokerage firms have already submitted their reports for MGX stocks, with H.C. Wainwright repeating the rating for MGX by listing it as a “Buy.” The predicted price for MGX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on May 07, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see MGX reach a price target of $6, previously predicting the price at $16. The rating they have provided for MGX stocks is “Neutral” according to the report published on May 02nd, 2024.
Wells Fargo gave a rating of “Overweight” to MGX, setting the target price at $25 in the report published on March 05th of the current year.
MGX Trading at 57.68% from the 50-Day Moving Average
After a stumble in the market that brought MGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.41% of loss for the given period.
Volatility was left at 16.98%, however, over the last 30 days, the volatility rate increased by 15.29%, as shares surge +87.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +93.33% upper at present.
During the last 5 trading sessions, MGX rose by +11.21%, which changed the moving average for the period of 200-days by -68.58% in comparison to the 20-day moving average, which settled at $3.02. In addition, Metagenomi Inc saw -63.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGX starting from Wapnick Pamela, who sale 1,559 shares at the price of $1.86 back on Dec 05 ’24. After this action, Wapnick Pamela now owns 61,492 shares of Metagenomi Inc, valued at $2,900 using the latest closing price.
Wapnick Pamela, the Chief Financial Officer of Metagenomi Inc, sale 6,265 shares at $2.88 during a trade that took place back on Sep 05 ’24, which means that Wapnick Pamela is holding 63,051 shares at $18,043 based on the most recent closing price.
Stock Fundamentals for MGX
Current profitability levels for the company are sitting at:
- -1.61 for the present operating margin
- 0.93 for the gross margin
The net margin for Metagenomi Inc stands at -1.34. The total capital return value is set at -0.28. Equity return is now at value -30.34, with -19.86 for asset returns.
Currently, EBITDA for the company is -56.02 million with net debt to EBITDA at -0.26. When we switch over and look at the enterprise to sales, we see a ratio of 2.94. The receivables turnover for the company is 93.51for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.18.
Conclusion
In conclusion, Metagenomi Inc (MGX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
